Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Edwards Lifesciences: Q3 Earnings Snapshot

10/27/2021 | 04:38pm EST

IRVINE, Calif. (AP) _ Edwards Lifesciences Corp. (EW) on Wednesday reported third-quarter profit of $340.1 million.

The Irvine, California-based company said it had profit of 54 cents per share.

The results exceeded Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of 53 cents per share.

The medical device maker posted revenue of $1.31 billion in the period, which fell short of Street forecasts. Nine analysts surveyed by Zacks expected $1.32 billion.

For the current quarter ending in December, Edwards Lifesciences expects its per-share earnings to range from 53 cents to 59 cents.

The company said it expects revenue in the range of $1.3 billion to $1.38 billion for the fiscal fourth quarter.

Edwards Lifesciences expects full-year earnings in the range of $2.07 to $2.27 per share, with revenue ranging from $5.2 billion to $5.4 billion.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EW at https://www.zacks.com/ap/EW

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about EDWARDS LIFESCIENCES CORPORATION
01/21SVB Leerink Adjusts Edwards Lifesciences Price Target to $132 From $135, Maintains Outp..
MT
01/19Edwards lifesciences to host earnings conference call on january 26, 2022
PR
01/18INSIDER SELL : Edwards Lifesciences
MT
01/10INSIDER SELL : Edwards Lifesciences
MT
01/07Morgan Stanley Raises Price Target for Edwards Lifesciences to $148 From $144, Maintain..
MT
01/07Credit Suisse Lifts Edwards Lifesciences' PT to $144 from $131, Keeps Outperform Rating
MT
01/05Edwards lifesciences to present at the 40th annual j.p. morgan healthcare conference
PR
01/03Evercore ISI Adjusts Edwards Lifesciences PT to $130 From $128, Outperform Rating Kept
MT
2021Edwards Secures FDA Clearance for SAPIEN 3 Heart Valve With Alterra Prestent
MT
2021Edwards receives fda approval for sapien 3 with alterra prestent for transcatheter pulm..
PR
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2021 5 255 M - -
Net income 2021 1 437 M - -
Net cash 2021 1 387 M - -
P/E ratio 2021 48,9x
Yield 2021 -
Capitalization 70 331 M 70 331 M -
EV / Sales 2021 13,1x
EV / Sales 2022 11,7x
Nbr of Employees 14 900
Free-Float 96,6%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | EW | US28176E1082 | MarketScreener
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 112,65 $
Average target price 130,67 $
Spread / Average Target 16,0%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors